Non-steroidal anti-inflammatory drugs request parity with Helicobacter pylori

References

• Shiotani A, Graham DY. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin North Am 2002; 86: 1447–66
   PubMed Web of Science ®Google Scholar
• Bennett PN, Davies P, Frigo GM, Weerasinghe WM, Lennard-Jones JE. Effect of diazepam on unstimulated and on stimulated gastric secretion. Scand J Gastroenterol 1975; 10: 101–3
   PubMed Web of Science ®Google Scholar
• Valnes K, Myren J, Wetterhus S, Larsen S, Dyb S, Ellekjaer EF, Halvorsen L, et al. Long-term treatment of duodenal ulcer with trimipramine. A double-blind study. Scand J Gastroenterol 1982; 17: 1003–7
   PubMed Web of Science ®Google Scholar
• Kirsner JB. Anticholinergic compounds in peptic ulcer. Gastroenterology 1957; 32: 953–5
   PubMedGoogle Scholar
• Cargill JM, Saunders JH, Peden N, Wormsley KG. Very long-term treatment of peptic ulcer with cimetidine. 1978; 2: 1113–15
   Google Scholar
• Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311–15
   PubMed Web of Science ®Google Scholar
• Forbes, GM, Glaser, ME, Cullen, DJ, Warren, JR, Christiansen, KJ, Marshall, BJ, Col, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet 1994;343:258–60.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. European Helicobacter Pylori Study Group (EHPSG). Current concepts in themanagement of Helicobacter pylori infection–the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167–80
   PubMed Web of Science ®Google Scholar
• Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. We started it–can we stop it?. Arch Intern Med 1986; 146: 1075–6
   PubMedGoogle Scholar
• Roth SH, Bennett RE. Non-steroidal anti-inflammatory drug gastropathy recognition and response. Arch Int Med 1987; 147: 2093–100
   PubMedGoogle Scholar
• Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers inpatients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9–13
   PubMed Web of Science ®Google Scholar
• Chan FKL GD. Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications–review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004; 19: 1051–61
   PubMed Web of Science ®Google Scholar
• Hawkey CJ. Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance. Aliment Pharmacol Ther 1999; 13: 695–702
   PubMedGoogle Scholar
• Fenn GC. Controversies in NSAID-induced gastroduodenal damage–do they matter?. Aliment Pharmacol Ther 1994; 8: 15–26
   PubMedGoogle Scholar
• Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicenter double blind, placebo-controlled trial. Lancet 1988; ii: 1277–80
   Google Scholar
• Silverstein FE, Graham GY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Int Med 1995; 123: 241–9
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727–34
   PubMed Web of Science ®Google Scholar
• Bombardiner C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8
   PubMedGoogle Scholar
• Sturkenboom MCJM, Burke TA, Dieleman JP, Tangelder MJD, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003; 42 Suppl 3: 23–31
   Google Scholar
• Bardell E, Gordon MM, Porter D. COX-2 inhibitors–implementation of the NICE guidelines. Rheumatology 2002; 41: 590–2
   PubMedGoogle Scholar
• National Institute for Clinical Excellence. Osteoarthritis and Rheumatoid Arthritis–COX II Inhibitors (No. 27). July 2001 (, , http://www.nice.org.uk. ).
   Google Scholar
• al-Assi MT, Genta RM, Karttunen TJ, Graham DY. Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use. Endoscopy 1966; 28: 229–33
   Google Scholar
• El-Zimaity HM, Genta RM, Graham DY. Histological features do not define NSAID-induced gastritis. Hum Pathol 1966; 27: 1348–54
   Google Scholar
• Shah K, Price AB, Talbot IC, Bardhan KD, Fenn CG, Bjarnason I. The effect of long-term misoprostol co-administration with nonsteroidal anti-inflammatory drugs: a histological study. Gut 1995; 37: 195–8
   PubMedGoogle Scholar
• Walt R. Drug therapy: misoprostol for the treatment of peptic ulcer and anti-inflammatory drug-induced gastroduodenal ulceration. N Engl J Med 1992; 327: 1575–80
   PubMed Web of Science ®Google Scholar
• Whittle BJR. Unwanted effects of aspirin and related agents on the gastrointestinal tract. Aspirin and other salicylates, JR Vane, RM Botting. Chapman & Hall Medical, London 1992; 465–509
   Google Scholar
• Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 301–14
   Google Scholar
• Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000–16
   PubMed Web of Science ®Google Scholar
• Vane JR, Botting RM. Overview–mechanisms of action of anti-inflammatory drugs. Improved non-steroidal anti-inflammatory drugs. COX-2 enzyme inhibitors, J Vane, J Botting, R Botting. Kluwer Academic Publishers, Dordrecht 1996; 1–27
   Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomised controlled trial. Celecoxib Long-term Arthritis Study. JAMA 2000; 284: 1247–55
   PubMed Web of Science ®Google Scholar
• Krag E. Gastric acid secretion related to prognosis in peptic ulcer disease. Acta Med Scand 1966; 180: 461–7
   PubMedGoogle Scholar
• Fry J. Peptic ulcer: a profile. Br Med J 1964; 2: 809–12
   PubMed Web of Science ®Google Scholar
• Bonnevie O. Survival in peptic ulcer. Gastroenterology 1978; 75: 1055–60
   PubMed Web of Science ®Google Scholar